AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...
When AstraZeneca acquired MedImmune in 2007 for $15 billion, some analysts felt the firm overpaid for the biotech company. This week, MedImmune celebrates its 25th anniversary – and has come to ...
AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a healthcare provider. FluMist ...
Some results have been hidden because they may be inaccessible to you